Medication info
Fosalong Plus D Tablet

Fosalong Plus D Tablet

Prescription medicationTabletOral
Ingredient · strength
Sodium Alendronate Hydrate›91.37mg / 1 tabletCholecalciferol Concentrate Powder›53.33mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
White to light yellow oblong tablet
Packaging
4 tablets (4 tablets/PTP x 1)
Approval status
Active

MFDS item code 201401931 · Approved 2014.04.21 · Insurance code 648507170

Summary

Main use
Treatment of osteoporosis in postmenopausal women and men
Who takes it
Adults · Children
Adult dose
Take 1 tablet (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with plenty of water, at least 30 minutes before consuming any food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The optimal duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. Discontinuation after 3~5 years of treatment should be considered in patients at low risk of fracture. Patients who discontinue treatment should be regularly reassessed for fracture risk. Other beverages or foods, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this medicine or at the same time may reduce the absorption of alendronate and decrease its effect. Take this medicine as soon as you get up in the morning and swallow it with plenty of water (170∼230 mL) to ensure rapid delivery to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after the first food intake. Do not take this medicine at bedtime or before getting up for the day. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients should take supplements if their dietary intake of calcium and vitamin D is inadequate (see Precautions for Use, 4. General Precautions, 2) Information to be Provided to Patients (4)). Patients at increased risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Once-weekly administration of this medicine provides one week's supply of vitamin D at 400 IU and 800 IU daily. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, then resume the usual weekly schedule on the originally scheduled day. Do not take 2 tablets on the same day. Use in older adults (65 years of age and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, administration of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min) because there is insufficient clinical experience.
Child dose
Children and adolescents (under 18 years of age): Safety and efficacy in children and adolescents have not been established.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women and men

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women and men.

How to take

Adult dose

Take 1 tablet (70 mg/2800 IU or 70 mg/5600 IU) once weekly in the morning with plenty of water, at least 30 minutes before consuming any food, beverages, or other medicines (see “General Precautions”). The appropriate dose for most patients with osteoporosis is 70 mg/5600 IU once weekly. The optimal duration of treatment has not been established. The safety and efficacy of this medicine for the treatment of osteoporosis are based on 4 years of clinical data. The need for continued treatment should be reassessed regularly in all patients receiving bisphosphonates. Discontinuation after 3~5 years of treatment should be considered in patients at low risk of fracture. Patients who discontinue treatment should be regularly reassessed for fracture risk. Other beverages or foods, including mineral water and barley tea, and medicines may reduce the absorption of alendronate (see “Interactions”). Consuming food within 30 minutes after taking this medicine or at the same time may reduce the absorption of alendronate and decrease its effect. Take this medicine as soon as you get up in the morning and swallow it with plenty of water (170∼230 mL) to ensure rapid delivery to the stomach and reduce the possibility of esophageal irritation. Do not lie down for at least 30 minutes after taking this medicine and until after the first food intake. Do not take this medicine at bedtime or before getting up for the day. Failure to follow these instructions may increase the risk of esophageal adverse reactions (see “Warnings” and “General Precautions”). Patients should take supplements if their dietary intake of calcium and vitamin D is inadequate (see Precautions for Use, 4. General Precautions, 2) Information to be Provided to Patients (4)). Patients at increased risk of vitamin D deficiency (e.g., patients over 70 years of age, patients in nursing homes, and patients with chronic diseases) may need additional vitamin D supplementation. Patients with gastrointestinal malabsorption syndrome may require higher doses of vitamin D supplements, and measurement of 25-hydroxyvitamin D levels should be considered. The recommended daily intake of vitamin D is 400 IU to 800 IU. Once-weekly administration of this medicine provides one week's supply of vitamin D at 400 IU and 800 IU daily. If a patient taking 1 tablet of this medicine forgets to take it on the scheduled day, take 1 tablet the next morning, then resume the usual weekly schedule on the originally scheduled day. Do not take 2 tablets on the same day. Use in older adults (65 years of age and older): No dose adjustment is necessary. Use in patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 35∼60 mL/min). However, administration of this medicine is not recommended in patients with severe renal impairment (creatinine clearance below 35 mL/min) because there is insufficient clinical experience.

Child dose

Children and adolescents (under 18 years of age): Safety and efficacy in children and adolescents have not been established.

Precautions

This medication can irritate the gastrointestinal mucosa, causing upper gastrointestinal adverse reactions such as esophagitis, esophageal ulcers, and esophageal erosions, thus caution is needed during intake. In particular, do not lie down for at least 30 minutes after taking the medication, and it should be taken with a sufficient amount of water to reduce the risk of esophageal irritation. If symptoms such as dysphagia, odynophagia, pain behind the sternum, or heartburn occur, discontinue use immediately and consult a physician. This medication should not be administered to patients with esophageal motility disorders or those who cannot sit upright or stand for more than 30 minutes, to patients with hypersensitivity to the drug's components, to patients with hypocalcemia, or to patients with certain genetic metabolic disorders. While taking this medication, adverse reactions such as indigestion, abdominal pain, nausea, constipation, diarrhea, musculoskeletal pain, headache, dizziness, and taste disturbances may occur, so caution is required. This medication should be taken with a gap from calcium supplements and antacids, and the risk of gastrointestinal adverse reactions may increase when used in conjunction with aspirin. During pregnancy, there may be risks to the fetus, so it should be administered only after consulting a physician, and caution is also needed for nursing mothers. It is not recommended for use in children, and it is not advisable to administer to elderly patients or those with severely impaired renal function. In case of overdose, hypocalcemia, gastrointestinal adverse reactions, etc. may occur, so immediate contact with a medical institution is necessary, and inducing vomiting should be avoided while maintaining an upright position. This medication should be stored out of the reach of children, and transferring to another container should be avoided.

Side effects

esophagitis, esophageal ulcer, esophageal erosion, esophageal obstruction, esophageal perforation, bleeding, dysphagia, odynophagia, retrosternal pain, heartburn, abdominal pain, nausea, dyspepsia, constipation, diarrhea, flatulence, gastroesophageal reflux, vomiting, abdominal distension, gastritis, musculoskeletal (bone, muscle, or joint) pain, muscle cramps, headache, dizziness, taste disturbance, rash, erythema, anastomotic ulcer, hives, angioedema, myalgia, malaise, asthenia, fever, symptoms of hypocalcemia, peripheral edema, oral pharyngeal ulcer, gastric ulcer, duodenal ulcer, osteomyelitis, jaw necrosis, joint swelling, low-energy fractures of the femoral head and other bones, dizziness, vertigo, pruritus, hair loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, scleritis, episcleritis, cholesteatoma of the external auditory canal, nasopharyngitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It should be stored at room temperature between 1°C and 30°C, and kept in a location protected from direct light to maintain its efficacy.

Appearance and packaging

Appearance

White to light yellow oblong tablet

Package unit

4 tablets (4 tablets/PTP x 1)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.